Cigarette Smoking Cessation Intervention for Buprenorphine Treatment Patients

Sharon M Hall, Gary L Humfleet, James J Gasper, Kevin L Delucchi, David F Hersh, Joseph R Guydish, Sharon M Hall, Gary L Humfleet, James J Gasper, Kevin L Delucchi, David F Hersh, Joseph R Guydish

Abstract

Introduction: Patients receiving medication assisted therapy (MAT) for opioid use disorder have high cigarette smoking rates. Cigarette smoking interventions have had limited success. We evaluated an intervention to increase cigarette abstinence rates in patients receiving buprenorphine-assisted therapy.

Methods: Cigarette smokers (N = 175; 78% male; 69% Caucasian; 20% Hispanic), recruited from a buprenorphine clinic were randomly assigned to either an extended innovative system intervention (E-ISI) or to Standard Treatment Control (STC). The E-ISI combined motivational intervention with extended treatment (long-term nicotine replacement therapy , varenicline, and extended cognitive behavioral therapy). STC received written information about quit-lines, medication, and resources. Assessments were held at baseline and 3, 6, 12, and 18 months. Seven-day biochemically verified point-prevalence cigarette abstinence was the primary outcome measure.

Results: Fifty-four percent of E-ISI participants entered the extended treatment intervention; E-ISI and STC differed at 3 months on abstinence status but not at months 6, 12, and 18. E-ISI participants were more likely to attempt to quit, to have a goal of complete abstinence, and to be in a more advanced stage of change than STC participants. A higher number of cigarettes smoked and the use of cannabis in the previous 30 days predicted continued smoking.

Conclusions: The E-ISI was successful in increasing motivation to quit smoking but did not result in long-term abstinence. The failure of treatments that have been efficacious in the general population to produce abstinence in patients receiving MAT of opioid use disorder suggests that harm reduction and other innovative interventions should be explored.

Implications: This study demonstrates that an intervention combining motivational interviewing with an extended treatment protocol can increase cigarette quit attempts, enhance cigarette abstinence goals, and further movement through stages of change about quitting smoking in patients receiving MAT for opioid use disorder who smoke cigarettes. The intervention did not increase abstinence rates over those observed in a standard treatment control, however. The latter finding supports those of earlier investigators who also failed to find efficacy for smoking cessation in this population and who also used interventions effective in the general population. This pattern of findings suggests that patients with opioid use disorder can be motivated to change smoking behavior, but alternative and innovative approaches to cigarette smoking treatment should be studied.

Trial registration: ClinicalTrials.gov NCT01350011.

Figures

Figure 1.
Figure 1.
CONSORT chart of participant flow from initial screening to 18-month follow-up.

References

    1. Nahvi S,Richter K,Li X,Modali L,Arnsten J. Cigarette smoking and interest in quitting in methadone maintenance patients.Addict Behav.2006;31(11):2127–2134.
    1. Clemmey P,Brooner R,Chutuape MA,Kidorf M,Stitzer M. Smoking habits and attitudes in a methadone maintenance treatment population.Drug Alcohol Depend.1997;44(2-3):123–132.
    1. Richter KP,Gibson CA,Ahluwalia JS,Schmelzle KH. Tobacco use and quit attempts among methadone maintenance J Public Health.2001;91(2):296–299.
    1. Wapf V,Schaub M,Klaeusler B,Boesch L,Stohler R,Eich D. The barriers to smoking cessation in Swiss methadone and buprenorphine-maintained patients.Harm Reduct J.2008;5:10.
    1. Chisolm MS,Fitzsimons H,Leoutsakos JM et al. . A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine.Nicotine Tob Res.2013;15(7):1297–1304.
    1. Pajusco B,Chiamulera C,Quaglio G et al. . Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine J Environ Res Public Health.2012;9(3):932–942.
    1. Adler NE,Ostrove JM. Socioeconomic status and health: what we know and what we don’t.Ann N Y Acad Sci.1999;896:3–15.
    1. Chait LD,Griffiths RR. Effects of methadone on human cigarette smoking and subjective ratings.J Pharmacol Exp Ther.1984;229(3):636–640.
    1. Schmitz JM,Grabowski J,Rhoades H. The effects of high and low doses of methadone on cigarette smoking.Drug Alcohol Depend.1994;34(3):237–242.
    1. Stark MJ,Campbell BK. Cigarette smoking and methadone dose J Drug Alcohol Abuse.1993;19(2):209–217.
    1. Mello NK,Lukas SE,Mendelson JH. Buprenorphine effects on cigarette smoking.Psychopharm.1985(86):417–425.
    1. Shiffman SM,Jarvik ME. Smoking withdrawal symptoms in two weeks of abstinence.Psychopharm.1976;50(1):35–39.
    1. Shiffman S,Gwaltney CJ,Balabanis MH et al. . Immediate antecedents of cigarette smoking: an analysis from ecological momentary assessment.J Abnorm Psychol.2002;111(4):531–545.
    1. Preble E,Casey JJ. Jr. Taking care of business: the heroin user’s life on the street. In:Smith DE,Gay GR, ’s So Good, Don’t Even Try It Once.Englewood Cliffs, NJ:Prentice-Hall;1972:97–118.
    1. Clarke JG,Stein MD,McGarry KA,Gogineni A. Interest in smoking cessation among injection drug J Addict.2001;10(2):159–166.
    1. Rohsenow DJ,Monti PM,Colby SM,Gulliver SB,Swift RM,Abrams DB. Naltrexone treatment for alcoholics: effect on cigarette smoking rates.Nicotine Tob Res.2003;5(2):231–236.
    1. Zullino D,Besson J,Schnyder C. Stage of change of cigarette smoking in alcohol-dependent patients.Eur Addict Res.2000;6(2):84–90.
    1. Story J,Stark MJ. Treating cigarette smoking in methadone maintenance clients.J Psychoactive Drugs.1991;23(2):203–215.
    1. Shoptaw S,Rotheram-Fuller E,Yang X et al. . Smoking cessation in methadone maintenance.Addiction.2002;97(10):1317–1328; discussion 1325.
    1. Sigmon SC,Miller ME,Meyer AC et al. . Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial.Addiction.2016;111(5):903–912.
    1. Stein MD,Weinstock MC,Herman DS,Anderson BJ,Anthony JL,Niaura R. A smoking cessation intervention for the methadone-maintained.Addiction.2006;101(4):599–607.
    1. Reid MS,Fallon B,Sonne S et al. . Smoking cessation treatment in community-based substance abuse rehabilitation programs.J Subst Abuse Treat.2008;35(1):68–77.
    1. Nahvi S,Ning Y,Segal KS,Richter KP,Arnsten JH. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial.Addiction.2014;109(9):1554–1563.
    1. Hall SM,Tsoh JY,Prochaska JJ et al. . Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical J Public Health.2006;96(10):1808–1814.
    1. Prochaska JO,Velicer WF,Fava JL,Rossi JS,Tsoh JY. Evaluating a population-based recruitment approach and a stage-based expert system intervention for smoking cessation.Addict Behav.2001;26(4):583–602.
    1. Baca CT,Yahne CE. Smoking cessation during substance abuse treatment: what you need to know.J Subst Abuse Treat.2009;36(2):205–219.
    1. Hall SM,Humfleet GL,Muñoz RF,Reus VI,Robbins JA,Prochaska JJ. Extended treatment of older cigarette smokers.Addiction.2009;104(6):1043–1052.
    1. Hall SM,Humfleet GL,Muñoz RF,Reus VI,Prochaska JJ,Robbins JA. Using extended cognitive behavioral treatment and medication to treat dependent J Public Health.2011;101(12):2349–2356.
    1. Humfleet G,Munoz R,Ling P,Reus V,Perez-Stable E,Hall SM. Smoking as a chronic health condition: a RCT comparing four extended smoking treatment interventions in a demographically diverse sample.Poster presented at Society for Research on Nicotine and Tobacco; March 3,2016;Chicago, IL.
    1. Sheehan DV,Lecrubier Y,Sheehan KH et al. . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J Clin Psychiatry.1998;59(Suppl 20):22–33;quiz 34.
    1. Jacob P 3rd,Hatsukami D,Severson H,Hall S,Yu L,Benowitz NL. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy.Cancer Epidemiol Biomarkers Prev.2002;11(12):1668–1673.
    1. Perkins KA,Karelitz JL,Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence.Nicotine Tob Res.2013;15(5):978–982.
    1. McNair DM,Lorr M,Droppleman LF.. Manual: Profile of Mood States (POMS). Revised.San Diego, CA:Educational and Instructional Testing Service;1992.
    1. Heatherton TF,Kozlowski LT,Frecker RC,Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance J Addict.1991;86(9):1119–1127.
    1. Fagerström K.Determinants of tobacco use and renaming the FTND to the Fagerstrom test for cigarette dependence.Nicotine Tob Res.2012;14(1):75–78.
    1. Ware JE Jr,Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.Med Care.1992;30(6):473–483.
    1. McLellan AT,Luborsky L,Woody GE,O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index.J Nerv Ment Dis.1980;168(1):26–33.
    1. Hall SM,Shi Y,Humfleet GL,Muñoz RF,Reus VI,Prochaska JJ. Smoking cessation abstinence goal in treatment-seeking smokers.Addict Behav.2015;42:148–153.
    1. Hughes JR,Hatsukami D. Signs and symptoms of tobacco withdrawal.Arch Gen Psychiatry.1986;43(3):289–294.
    1. Prochaska JO,Velicer WF,DiClemente CC,Fava J. Measuring processes of change: applications to the cessation of smoking.J Consult Clin Psychol.1988;56(4):520–528.
    1. Hudmon KS,Corelli RL,Chung E et al. . Development and implementation of a tobacco cessation training program for students in the health professions.J Cancer Educ.2003;18(3):142–149.
    1. Hollander M,Wolfe DA.. Nonparametric Statistical Methods.2ndedNew York:Wiley;1999.
    1. Prochaska J,Fromont S,Hall S et al. . Brief Versus Extended Tobacco Treatment Initiated in Inpatient Psychiatry: a Randomized Controlled Trial.Philadelphia, PA:Society for Research on Nicotine and Tobacco;2015.
    1. Prochaska JJ,Hall SE,Delucchi K,Hall SM. Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled J Public Health.2014;104(8):1557–1565.
    1. Shoptaw S,Jarvik ME,Ling W,Rawson RA. Contingency management for tobacco smoking in methadone-maintained opiate addicts.Addict Behav.1996;21(3):409–412.
    1. Stein MD,Caviness CM,Kurth ME,Audet D,Olson J,Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.Drug Alcohol Depend.2013;133(2):486–493.
    1. Miller ME,Sigmon SC. Are pharmacotherapies ineffective in opioid-dependent smokers? Reflections on the scientific literature and future directions.Nicotine Tob Res.2015;17(8):955–959.
    1. Gourlay SG,Forbes A,Marriner T,Pethica D,McNeil JJ. Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation.BMJ.1994;309(6958):842–846.
    1. Metrik J,Spillane NS,Leventhal AM,Kahler CW. Marijuana use and tobacco smoking cessation among heavy alcohol drinkers.Drug Alcohol Depend.2011;119(3):194–200.
    1. Humfleet G,Munoz R,Sees K,VI R,Hall S. History of alcohol or drug abuse problems, use of alcohol or marijuana, and success in quitting smoking.Addict Behav.1999;24(1):149–154.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi